Samsung Bioepis develops high-dose SC technology to expand biosimilars

Samsung Bioepis, a company affiliated with Samsung Epice Holdings, has secured mastery of a new technology capable of changing intravenous to subcutaneous (SC) formulations. The innovation is based on recombinant human hyaluronidase (PH20) and could allow the company to expand its presence in the biosimilars market, in a scenario where large pharmaceutical companies seek to convert popular medicines for SC application, intensifying the competition for patents.
Internal tests of the SC modification technology, using the PH20, were completed by Samsung Bioepis, according to data released by the biotechnology industry. The company achieved significant progress by developing its own methods for cultivation and purification, in addition to producing its own hyaluronidase. This approach distinguishes Samsung Bioepis from competitors such as Halozyme in the United States and Alteogen in Korea, and is seen as a crucial strategy for avoiding intellectual property litigation, given that both the substance and the processes are subject to patents.
The ability to convert medications from intravenous (IV) to subcutaneous (SC) formulations, especially those based on antibodies in high doses, fundamentally depends on the technology that employs PH20. In previous cases, such as Benepali SC (derived from Enbrel) and Imraldi SC (derived from Humira), Samsung Bioepis was able to develop SC versions with simple adjustments, as they were drugs with a low dose of antibodies. However, new and more effective cancer drugs, which often have high doses, require the use of PH20-based technology, which temporarily acts on the subcutaneous tissue barrier to allow absorption.
The expectation is that Samsung Bioepis will apply this innovation to high-impact medicines, such as Keytruda, the most sold cancer drug in the world, developed by Merck (MSD) and currently in the development phase as a biosimilar. Another potential target is Enhertu, a leading antibody-drug conjugate (ADC) from Japanese company Daiichi Sankyo. A spokesperson for Samsung Bioepis, however, stated that “nothing has been officially decided on which medicines the technology will be used in.”






